Picodya’s new technology enables real-time monitoring of human immune status

The company is the creator of the first hybrid in vitro diagnostics (IVD) solution for multiplexed point-of-care testing (xPOCT) and announced the deployment of its B-Matrix technology in National Institutes of Health (NIH) laboratories.

Picoyda says this could further the PREMISE (Pandemic REsponse REpository through Microbial and Immune Surveillance and Epidemiology) goal of establishing a pre-emptive repository of candidate immunobiological countermeasures.

Picodya’s B-Matrix platform is the first xPOCT IVD solution that performs both molecular and immunoassays from many body fluids on a single platform. The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, considerably shortening the diagnostic timeline.

“With our knowledge of the devastating impact of Covid-19 on global health and following years of research collaboration with the NIH for crisis preparedness, we are proud to proceed with the next phase of this important partnership,” said Tzvika Barkai, founder and chief executive officer at Picodya.

“We remain dedicated to enabling timely, precise, and comprehensive disease diagnosis capabilities to optimize potential outcomes. We plan to introduce the B-Matrix solution to additional research labs across the US, followed by the broader clinical market.”

The NIH and its National Institute of Allergy and Infectious Diseases (NIAID) established PREMISE in 2021 to prepare for pandemic outbreaks.

PREMISE partnered with Picodya during the initial phases of development to install the B-Matrix technology at NIAID Vaccine Research Center’s (VRC) laboratories to detect reactivity to multiple potential pandemic threats.

Leave a Reply

Your email address will not be published. Required fields are marked *